Press Releases Archives - Page 2 of 103 - Lupin

BSE 2300.00 NSE 2307.90

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2300.00 NSE 2307.90

Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain

December 12, 2025

Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets

December 5, 2025

Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ (Pegfilgrastim-unne) in the United States

December 4, 2025

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne)

December 1, 2025

Lupin Foundation Earns CRISIL’s Highest VO 1A Rating for Excellence in Social Responsibility

November 28, 2025

Lupin Announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations

November 15, 2025

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™

November 14, 2025

Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91

November 13, 2025

Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility

November 12, 2025

Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India

November 12, 2025

1 2 3 … 102 103

Search

Hit enter to search or ESC to close